144P Subclinical cholestasis as a hallmark of gut dysbiosis causing resistance to cancer immunotherapy

A-L. Mallard de la Varende; H. Guillaume dit Taunière; Sylvère Durand; Thomas Simon; Daniel Suissa; F-X. Danlos; Aurélien Marabelle; Caroline Truntzer; A. Fouquier; C. Alves Costa Silva; Federica Marmorino; Chiara Cremolini; Paula A. Bousquet; Sebastian Meltzer; Anne Hansen Ree; François Ghiringhelli; Guido Guido Kroemer; Lisa Derosa; L. Zitvogel; Marine Fidelle

doi:10.1016/j.annonc.2025.08.578

Related publications

Article2020

IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice

Luísa Hahn, Nora Helmrich, Diran Herebıan, Ertan Mayatepek, Uta Drebber, Eugen Domann, Stefan Olejniczak, Markus Weigel, Torsten Hain, Timo Räth, Stefan Wirtz, Hans‐Joachim Mollenkopf, Nadine Schmidt, Christa Ewers, A Baier, Y Churin, Anita Windhorst, Ralf Weiskirchen, Ulrich Steinhoff, Elke Roeb, M Roderfeld

Article2024

562 Bile acids circumvent gut dysbiosis-induced resistance to anti-PD-1

Anne-Laure Mallard de La Varende, Ai-Ling Tian, Clara Sehl, Imran Lahmar, Pierre Ly, Sylvère Durand, Guido Guido Kroemer, Kristina Schoonjans, Laurence Zitvogel, Marine Fidelle

Article2020

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Lisa Derosa, Bertrand Routy, Marine Fidelle, Valerio Iebba, Laurie Alla, Edoardo Pasolli, Nicola Segata, Aude Desnoyer, Filippo Pietrantonio, Gladys Ferrere, Jean‐Eudes Fahrner, Emmanuelle Le Chatellier, Nicolas Pons, Nathalie Galleron, Hugo Roume, Connie P.M. Duong, Laura Mondragón, Kristina Iribarren, Mélodie Bonvalet, Safae Terrisse, Conrad Rauber, Anne‐Gaëlle Goubet, Romain Daillère, Fabien Lemaître,

Article2023

Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy

Andrew Maltez Thomas, Marine Fidelle, Bertrand Routy, Guido Guido Kroemer, Jennifer A. Wargo, Nicola Segata, Laurence Zitvogel

Article2020

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Romain Daillère, Lisa Derosa, Mélodie Bonvalet, Nicola Segata, Bertrand Routy, Manuela Gariboldi, Eva Budínská, I. Jolanda M. de Vries, Alessio Naccarati, Valérie Zitvogel, Carlos Caldas, Lars Engstrand, Sibylle Loibl, Jacques Fieschi, Lucie Heinzerling, Guido Guido Kroemer, Laurence Zitvogel

144P Subclinical cholestasis as a hallmark of gut dysbiosis causing resistance to cancer immunotherapy

Discussion(0)

Related publications

IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice

562 Bile acids circumvent gut dysbiosis-induced resistance to anti-PD-1

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy